The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biomarkers in Rheumatoid Arthritis Remain Elusive

Biomarkers in Rheumatoid Arthritis Remain Elusive

February 1, 2015 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although a combination of medications in a treat-to-target approach will work for most patients, some people are completely refractory to any therapy. “Rather than cycling through three or four treatments, a biomarker could help you pick the ideal treatment,” Dr. Rigby says. Although RA is a polygenic disorder and can be divided between seropositive and seronegative disease, “those distinctions have really not had that much power in terms of guiding therapy.”

You Might Also Like
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
Explore This Issue
February 2015
Also By This Author
  • The ACR/ARHP Annual Meeting: Rheumatoid Arthritis Raises Mortality Risk in Women

Targets with Potential

William Robinson, MD, associate professor of immunology and rheumatology at Stanford School of Medicine (Calif.), says the objective is to “create biomarkers that are informative in different dimensions than DAS scores. DAS scores simply measure current disease activity, and we need biomarkers that can predict response to therapy.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

There are no good candidates currently for biomarkers that could be used to identify subsets of patients likely to respond to a particular therapy, but the “overarching objective is to develop such in the future.” Mechanistic biomarkers offer the greatest potential, Dr. Robinson says. In a recent article in Nature Reviews Rheumatology, Dr. Robinson and colleagues explained that a mechanistic biomarker is directly involved in the pathogenesis of a disease, enables differentiation of distinct subtypes of the same disease, can be used to stratify disease and target treatment, and could indicate whether a therapy is targeting the cause of a disease.1

In rheumatology, defining a new molecular taxonomy of disease and the subsequent identification of diagnostic, predictive and prognostic mechanistic biomarkers begins with first stratifying current clinical classifications and identifying molecular pathways that mediate the pathogenesis of disease, they wrote.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We anticipate that involvement of certain molecular pathways will be shared across subsets of multiple different rheumatic diseases, whereas other pathways will be disease specific. Molecular classification of disease could enable the identification of disease subtypes that are responsive to specific therapeutics and eventually the use of patient-derived biomarkers for guiding target therapy,” they said.

Incremental research is underway to identify mechanistic biomarkers that may one day guide therapy. A study by Dennis and colleagues in Arthritis Research & Therapy used genome-wide expression analysis of synovial tissues from a large RA cohort to look for potential biomarkers.2 The researchers used a combination of global gene expression, histologic and cellular analyses, and analysis of gene expression data. That research defined molecular and cellular phenotypes that reflect the wide heterogeneity present in RA synovium.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Biomarkers, Holliman, Rheumatoid arthritisIssue: February 2015

You Might Also Like:
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.